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Abstract The common neurotrophin receptor p75NTR, a mem-
ber of the tumor necrosis factor (TNF) receptor superfamily,
plays an important role in several cellular signaling cascades,
including that leading to apoptosis. FAP-1 (Fas-associated
phosphatase-1), which binds to the cytoplasmic tail of Fas, was
originally identified as a negative regulator of Fas-mediated
apoptosis. Here we have shown by co-immunoprecipitation that
FAP-1 also binds to the p75NTR cytoplasmic domain in vivo
through the interaction between the third PDZ domain of FAP-1
and C-terminal Ser-Pro-Val residues of p75NTR. Furthermore,
cells expressing a FAP-1/green fluorescent protein showed
intracellular co-localization of FAP-1 and p75NTR at the plasma
membrane. To elucidate the functional role of this physical
interaction, we examined TRAF6 (TNF receptor-associated
factor 6)-mediated NF-UB activation and tamoxifen-induced
apoptosis in 293T cells expressing p75NTR. The results revealed
that TRAF6-mediated NF-UB activation was suppressed by
p75NTR and that the p75NTR-mediated NF-UB suppression was
reduced by FAP-1 expression. Interestingly, a mutant of the
p75NTR intracellular domain with a single substitution of a Met
for Val in its C-terminus, which cannot interact with FAP-1,
displayed enhanced pro-apoptotic activity in 293T transfected
cells. Thus, similar to Fas, FAP-1 may be involved in suppressing
p75NTR-mediated pro-apoptotic signaling through its interaction
with three C-terminal amino acids (tSPV). Thus, FAP-1 may
regulate p75NTR-mediated signal transduction by physiological
interaction through its third PDZ domain.
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1. Introduction
p75NTR is a neurotrophin receptor, a member of the tumor
necrosis factor (TNF) receptor superfamily, which includes
TNF receptor (TNFR) 1, TNFR2, CD40, and Fas [1].
Upon ligation with nerve growth factor (NGF), p75NTR trans-
duces a variety of signal cascades, including NF-UB activation
[2], sphingomyelin hydrolysis [3], and apoptosis [4^8], inde-
pendent of TrkA receptors. p75NTR also binds with similar
a⁄nity to brain-derived neurotrophic factor, neurotrophin
(NT) 3, and NT-4/5 [9,10]. Structural analysis by nuclear
magnetic resonance reveals that the cytoplasmic region of
p75NTR has six K-helical folds, similar to the subtype 1 ‘death
domain’ of the TNF receptor superfamily [11]. Recent analy-
sis indicated that TNF receptor-associated factor 6 (TRAF6)
can physically associate with p75NTR and can function as a
signal transducer for NGF action [12]. However, the molec-
ular mechanisms by which NGF/p75NTR regulates those
events remain unclear.
Fas-associated phosphatase-1 (FAP-1), also known as pro-
tein-tyrosine phosphatase (PTP)-BAS [13], PTP-L1 [14],
hPTP1E [15], and PTP-BL [16], was previously identi¢ed by
yeast two-hybrid screening as a negative regulator that binds
to the cytoplasmic tail of Fas (APO-1/CD95) [17]. FAP-1 has
a putative membrane binding domain similar to those found
in ezrin family proteins and six PDZ domains. PDZ domains
(also called GLGF repeats or DHR domains) consisting of
80^90 amino acids have been found in a number of intracel-
lular proteins (reviewed in [18^20]). Recently, proteins with
PDZ domains have been reported to bind to the C-terminal
motif t(S/T)-X-V, including the PSD-95/N-methyl-D-aspartate
(NMDA) receptor, the PSD-95/Shaker-type K channel, and
Dlg-APC interactions [19,20]. Thus, the PDZ domain is a
novel motif for protein-protein interactions that may partic-
ipate in signal transduction or cell-cell interactions. Recent
work of ours clearly showed that the third PDZ domain of
FAP-1 speci¢cally recognizes the three C-terminal amino acid
residues SLV of Fas [21]. Using combinatorial peptide libra-
ries, we and others have determined that the consensus motif
for the interaction with the third PDZ domain of Fas is
t(S/T)-X-(V/L/I) [21,22]. The highest a⁄nity was found in
the C-terminal amino acid residue V. This binding character-
istic provides the hypothesis that the third PDZ domain of
FAP-1 may also bind to the C-termini of other receptors with
the t(S/T)-X-V motif. As the last three amino acids of p75NTR,
SPV, are conserved among chicken, rat, and human, we ex-
amined whether FAP-1 interacts with the C-terminal cytoplas-
mic region of p75NTR. Our results indicate that FAP-1 is
capable of binding to the C-terminal SPV of p75NTR both
in vitro and in vivo. Moreover, we provide evidence that the
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interaction between FAP-1 and p75NTR may be functionally
involved in p75NTR-mediated signal transduction.
2. Materials and methods
2.1. Construction of mammalian expression vectors
Rat p75NTR expression plasmid constructs pcDNA3-p75NTR inter-
cellular domain (ICD) (V396M) and pcDNA3-p75NTR-IC were made
by polymerase chain reaction (PCR). The common forward primer
(5P-CGGGATCCATGAAGAGGTGGAACAGC-3P) for both con-
structs contains a BamHI site (underlined). The reverse primer (5P-
TGCGGTCGACTCACATTGGGGATGTGGCAGTGGA-3P) for
mutant p75NTR-ICD (V396M) contains a SalI site (underlined), and
substitutes valine with methionine at residue 396. The PCR products
of these primers were digested with BamHI and SalI and ligated into
the BamHI and XhoI sites of pcDNA3 (Invitrogen) to generate
pcDNA3-p75NTR-ICD (V396M). The reverse primer (5P-GCTCTA-
GAACATCAGTCGTCGGA-3P) for the wild-type p75NTR contains
an XbaI site (underlined). The products of the PCR using this reverse
primer and the above forward primer were ligated into the BamHI
and XbaI sites of pcDNA3 to generate pcDNA3-p75NTR-ICD.
pcDNA3-p75NTR (V396M, vSPV) was constructed by inserting a
full-length p75NTR cDNA fragment ampli¢ed with a forward primer
(5P-CCCAAGCTTCCACCATGAGGAGGGCAGGTGCTGCCT-3P)
and a reverse primer (5P-CCGCTCGAGTCACATTGGGGATGTG-
GCAGTGGA-3P for V396M, 5P-CCGCTCGAGTCATGTGGCAG-
TGGACTCGCTGCAT-3P for vSPV) into the HindIII and XhoI sites
of pcDNA3. pcDNA3-hp75NTR was constructed by inserting a full-
length human p75NTR cDNA into the EcoRI site of the pcDNA3
vector. Human FAP-1 expression plasmid pRc/CMV-hFAP-1 was
constructed by inserting the NotI cassette of the human full-length
FAP-1 cDNA into the NotI site of pRc/CMV (Invitrogen). Human
FAP-1 expression plasmid pEGFP-hFAP-1 was constructed by sub-
cloning a complete coding sequence in-frame at the SacI-SmaI sites of
the pEGFP-N2 vector (Clontech). FAP-1 tagged with FLAG was
prepared by using pFLAG-CMV2 and a PCR-ampli¢ed cDNA frag-
ment encompassing the protein-coding region. pCMV-myc-mouse
TRAF6 was a gift of MBL Co., Ltd.
2.2. Preparation of glutathione S-transferase (GST) fusion proteins
and in vitro binding assays
DNA fragments encoding truncated variants of rat p75NTR ^ amino
acids 245^396 (a whole cytoplasmic region), 245^337, 302^396, 302^
337, 338^396, and 245^393 (v Ser-Pro-Val) ^ were ampli¢ed from rat
p75NTR cDNA by PCR and subcloned at the EcoRI-SalI sites of the
pGEX-4T-1 vector (Pharmacia). Sense and antisense oligonucleotides
connected with EcoRI and SalI sites, respectively, which encode Ser-
Pro-Val (corresponding to amino acids 394^396 of rat p75NTR) or Ser-
Pro-Met, were synthesized. After annealing of both strands, they were
subcloned at the EcoRI-SalI sites of the pGEX-4T-1 vector. The
p75NTR deletion mutants and Ser-Pro-Met were expressed as GST
fusion proteins by using these constructs in INVKFP (Invitrogen) by
induction with 0.5 mM isopropyl-L-D-thiogalactopyranoside for 4 h at
37‡C. GST fusion proteins were a⁄nity-puri¢ed from bacterial lysates
with glutathione Sepharose 4B beads (Pharmacia Biotech).
[35S]Methionine-labeled proteins were generated with the TNT-
coupled reticulocyte lysate system (Promega), and HFAP-10 cDNA
(human FAP-1/PTP-BAS type 1 nucleotides 3897^5710) was sub-
cloned into the Bluescript vector pSK-II (Stratagene), or HFAP-11
cDNA (human FAP-1/PTP-BAS type 1 nucleotides 4030^5525, en-
coding amino acids 1323^1821) was subcloned into the pcDNA 3.1-
Myc-His vector (Invitrogen). 35S-labeled product from pSK-II-HFAP-
10 was in vitro translated from an internal methionine codon to give
the peptides corresponding to amino acids 1323^1882 of human FAP-
1. Following translation, 5 Wl of total 35S-labeled reticulocyte lysate
was diluted into 200 Wl of NETN bu¡er (100 mM NaCl, 1 mM
EDTA, 20 mM Tris [pH 8.0], 0.2% NP40) and incubated with 10 Wl
of a 50% slurry of GST- or GST-fusion-protein-Sepharose beads for
4^16 h at 4‡C. The beads were then pelleted, washed six times in
NETN bu¡er, boiled in SDS sample bu¡er, and resolved on SDS-
polyacrylamide gel. Bound proteins were made visible following auto-
radiography after enhancing the signal by Amplify (Amersham).
For coprecipitation experiments on native FAP-1 with the GST-
p75NTR C-terminus, 293T cells growing in a 10 cm dish were transi-
ently transfected with pRc/CMV-hFAP-1 by the calcium/phosphate
procedure [23]. At 48^60 h after transfection, the cells were lysed in
1 ml of NETN bu¡er containing protease inhibitors (1 mM PMSF,
0.28 TIU/ml aprotinin, 50 Wg/ml leupeptin, 1 mM benzamidine, 0.7
Wg/ml pepstatin) for 30 min on ice, and the insoluble fraction was
removed by centrifugation. The resulting supernatant was incubated
with GST-p75NTR (338^396) or GST alone, each being immobilized
on 20 Wl of glutathione Sepharose beads for V12 h at 4‡C, then
washed with NETN bu¡er and boiled in SDS sample bu¡er. The
retained FAP-1 on beads was resolved on SDS-polyacrylamide gel
(5%) and analyzed by Western blotting using anti-FAP-1 polyclonal
antibody at 2 Wg/ml.
2.3. Cell culture, transfection, and in vivo binding assays
293T cells were grown and maintained in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37‡C and 5% CO2. These cells were seeded in 10 cm plates at
2U106 cells per plate and transiently transfected with 20 Wg of
pFLAG-CMV-2-hFAP-1, pcDNA3-p75NTR, or both plasmids. Trans-
fected cells were cultured for 24 h and lysed in 1 ml of NETN bu¡er
containing protease inhibitors. The supernatant was immunoprecipi-
tated with 2 Wg of anti-FLAG M2 monoclonal antibody (Sigma)
coupled with protein G Sepharose 4B (Pharmacia) at 4‡C for 2 h.
They were washed ¢ve times with the same bu¡er and subjected to
SDS-PAGE (7.5%). The samples were then transferred to nitrocellu-
lose membrane and immunoblotted by rabbit polyclonal anti-p75NTR
antibody.
2.4. Reporter gene assays
293T cells were seeded in six well plates at 1.2U105 cells per well
and transiently transfected with 5 Wg of plasmids containing 1.4 Wg of
pELAM-luc reporter plasmid (a gift of MBL Co., Ltd.) and 0.1 Wg of
pRL-TK as an internal control (Promega), using the calcium/phos-
phate method. Twenty-four hours after transfection, the cells were
washed twice with phosphate-bu¡ered saline (PBS) and lysed in 0.5
ml of lysis bu¡er (Dual-Luciferase Reporter Assay System, Promega).
Lysate (10 Wl) was mixed with 50 Wl of luciferase assay reagent. Lu-
ciferase activity was measured in a model LB9507 luminometer (EG
and G Berthold, Germany).
2.5. Cell viability assays
293T cells were plated at a density of 5U105 in six well plates and
transfected as described above. Eighteen hours after transfection, the
cells were washed with serum-free medium and placed on DMEM
with 3% FBS. After a further 18^24 h incubation, the cells were
placed on 35 WM tamoxifen (Sigma) to induce apoptosis and incu-
bated for 4^12 h. Viability was assessed by propidium iodide £uores-
cence [24] and trypan blue exclusion [4].
2.6. Fluorescence analysis
293T cells were plated on a poly-L-Lys-coated cover glass and tran-
siently transfected with pEGFP-hFAP-1 or pcDNA3-p75NTR. Cells on
the cover glass were ¢xed with 2.5% paraformaldehyde/PBS for 30
min at room temperature. For the detection of p75NTR, ¢xed cells
were incubated with 5 Wg/ml monoclonal anti-rat NGF receptor anti-
body (which reacts with low-a⁄nity rat NGFR; Boehringer Mann-
heim) for 2 h at 4‡C. Cells were rinsed with PBS twice and subse-
quently incubated for 2 h at 4‡C with 5 Wg/ml of goat anti-mouse IgG
antibody conjugated with Cy5 (Jackson ImmunoResearch Laborato-
ries). Cells on the cover glass were then mounted on a glass slide in
glycerin jelly for microscopic measurement with a Zeiss LSM 510
confocal laser scanning microscope, equipped with a U40 objective
(Zeiss). An excitation line of 488 nm Ar laser was used for green
£uorescent protein (GFP) detection and 647 nm Kr line was used
for Cy5 (p75NTR) detection.
3. Results
3.1. FAP-1 interacts with the C-terminal SPV of p75NTR in
vitro
To investigate the interaction of FAP-1 with the cytoplas-
mic tSPV of p75NTR, we used an in vitro binding assay. The
GST fusion proteins including the cytoplasmic regions of
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p75NTR, CD40, TNFR1, and TNFR2 were expressed in Es-
cherichia coli and a⁄nity-puri¢ed on glutathione Sepharose.
HFAP-10 polypeptide containing the third PDZ domain (ami-
no acids 1323^1882 of human FAP-1) was in vitro translated
and tested for binding to these GST fusion proteins in vitro.
HFAP-10 polypeptide was coprecipitated with the GST fusion
protein containing the cytoplasmic domain of p75NTR as well
as that containing the human Fas C-terminal amino acids
SLV; it did not interact with the GST fusion proteins con-
taining the cytoplasmic domains of CD40, TNFR1, and
TNFR2, which do not possess the C-terminal t(S/T)-X-V mo-
tif (Fig. 1A). To determine the minimum region of p75NTR
necessary for interaction with FAP-1, a series of p75NTR cy-
toplasmic truncated mutants were prepared as GST fusion
proteins and were tested for binding to the in vitro translated
HFAP-10 polypeptide. The results indicate that 35S-labeled
HFAP-10 polypeptide was associated with p75NTR truncation
mutants containing the intact C-terminus and was bound to
the C-terminal amino acid residues SPV of p75NTR (Fig. 1B^
D). To further con¢rm this result, we also used a C-terminal
truncation mutant of p75NTR (245^393), vSPV, in which the
last three amino acids were deleted. In an in vitro binding
assay, this mutant, lacking tSPV, did not retain FAP-1 bind-
ing activity (Fig. 1B,D), leading to the conclusion that the C-
terminal amino acids SPV of p75NTR are necessary and su⁄-
cient for the binding to FAP-1.
We also did an in vitro binding assay using in vitro trans-
lated FAP-1 polypeptide (HFAP-11) and GST fusion proteins
containing the three amino acids SPM or SPV at their C-
termini. The results indicate that the FAP-1 polypeptide in-
teracted with GST-SPV as well as with other GST fusion
proteins retaining the cytoplasmic tSPV motif of p75NTR,
whereas GST-SPM failed to associate with FAP-1 (Fig.
1C,D). These results strongly support previous ¢ndings that
the third PDZ domain of FAP-1 speci¢cally recognizes the
C-terminal sequence motif t(S/T)-X-V [28,29].
Fig. 1. Interaction of FAP-1 with p75NTR cytoplasmic region in vitro. A: In vitro binding of HFAP-10 with various receptors of the TNF re-
ceptor superfamily. The cytoplasmic region of several receptors-rat p75NTR, CD40, TNFR1, TNFR2, and the C-terminal amino acid residues
SLV of human Fas-were prepared as GST fusion proteins. The GST fusion proteins, immobilized on glutathione-Sepharose beads, were incu-
bated with 35S-labeled in vitro translated HFAP-10 peptide containing the third through ¢fth PDZ domains of human FAP-1 protein. After
the beads were washed, retained HFAP-10 peptide was analyzed by 10% SDS-PAGE and autoradiography. B: Interaction of FAP-1 (HFAP-
10) with various p75NTR deletion mutants in vitro. 35S-labeled HFAP-10 polypeptide, corresponding to amino acids 1323^1882 of human FAP-
1, was incubated with the indicated GST fusion proteins of p75NTR-truncated peptides. C: FAP-1 is incapable of binding to C-terminal SPM.
35S-labeled HFAP-11 was incubated with the indicated GST fusion proteins immobilized on glutathione Sepharose beads. After the beads were
washed, retained HFAP-11 protein was analyzed by SDS-PAGE and autoradiography. Molecular size markers are shown at the left in kDa.
D: Schematic representation of rat p75NTR deletion mutants and interaction with HFAP-10. The mature rat p75NTR is a 396 amino acid pro-
tein with a single transmembrane domain. The cytoplasmic region consisting of 152 amino acids possesses a death domain (amino acids 325^
390 of mature rat p75NTR) and a C-terminal t(S/T)-X-V motif. The results of the interactions of HFAP-10 with p75NTR deletion mutants shown
in B are indicated here by + or 3 signs. N = NH2-terminal. C = COOH-terminal. TM = transmembrane domain, amino acids 223^244.
DD = death domain (hatched), amino acids 325^390. tSPV = C-terminal SPV (solid), amino acids 394^396.
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3.2. FAP-1 interacts with p75NTR in vivo
To con¢rm the interaction of full-length FAP-1 protein
with p75NTR, an in vitro pull-down assay was done using
cell lysates extracted from human embryonic kidney cell line
293T, which overexpresses FAP-1. Overexpression of FAP-1
protein in 293T cells transiently transfected with pRc/CMV-
hFAP-1 was con¢rmed by Western blot analysis to have an
apparent molecular mass of V250 kDa (Fig. 2A, lane 3). The
results clearly indicate that GST-p75NTR (59 C-terminal ami-
no acids, 338^396) pulled down the full length of the FAP-1
protein but that GST alone did not (Fig. 2A, lanes 1 and 2).
To determine whether FAP-1 interacts with p75NTR in vivo,
we coexpressed FLAG epitope-tagged FAP-1 with p75NTR in
293T cells, and immunoprecipitated it from cell extracts by
using anti-FLAG M2 monoclonal antibody (Fig. 2B). Co-im-
munoprecipitate of p75NTR was clearly detected by Western
blotting using anti-p75NTR antibody (Fig. 2B, lane 4), but
p75NTR proteins were not detected in the anti-FLAG mono-
clonal antibody immunoprecipitate from cells transfected with
a FLAG-tagged FAP-1 expression plasmid without p75NTR
(Fig. 2B, lane 3), or with a p75NTR expression plasmid with-
out a FLAG-tagged FAP-1 (Fig. 2B, lane 2).
3.3. Co-localization of FAP-1 and p75NTR
To examine the subcellular localization of FAP-1 and
p75NTR, 293T cells were cotransfected with expression plas-
mids encoding hp75NTR and GFP-FAP-1 fusion protein.
As expected from the presence of a putative membrane bind-
ing domain in FAP-1, FAP-1 fusion protein was localized
mostly at the plasma membrane (Fig. 3A). p75NTR was also
located at the plasma membrane (Fig. 3B). Superimposition
of the expression patterns of GFP-FAP-1 and p75NTR indi-
Fig. 2. FAP-1 interacts with p75NTR in vivo. A: Cell lysate prepared from 293T cells transiently transfected with an expression vector encoding
human FAP-1 (pRc/CMV-hFAP-1) was incubated with GST or GST-p75NTR (338^396) (59 C-terminal amino acids) immobilized on gluta-
thione-Sepharose beads. After incubation, the beads were washed, and retained FAP-1 protein was analyzed by Western blotting with anti-
FAP-1 polyclonal antibody (lanes 1 and 2). Cell lysate before precipitation with GST fusion proteins was also analyzed (lane 3). B: Cell lysates
prepared from 293T cells transiently transfected with control vectors pcDNA3 and pFLAG-CMV-2 (lane 1), pcDNA3-rat p75NTR (lane 2),
pFLAG-CMV-2-hFAP-1 (lane 3), and pFLAG-CMV-2-hFAP-1 and pcDNA3-rat p75NTR (lane 4) were immunoprecipitated with anti-FLAG
M2 monoclonal-antibody-coupled protein G Sepharose 4B. After incubation, the beads were washed, and retained p75NTR protein was analyzed
by Western blotting with anti-p75NTR polyclonal antibody.
Fig. 3. Co-localization of FAP-1 and p75NTR. Subcellular localization of FAP-1 and p75NTR in transfected 293T cells. 293T cells were cotrans-
fected with pEGFP-hFAP-1 and pcDNA3-hp75NTR. Twenty-four hours after transfection, cells were ¢xed. A: p75NTR was detected with an
anti-p75NTR polyclonal antibody and a phycoerythrin-conjugated anti-rabbit IgG F(AbP)2 (red). B: GFP-hFAP-1 was detected by its green £uo-
rescence (green). C: Co-localization of p75NTR and GFP-hFAP-1 in the plasma membrane was detected by using combined £uorescence (yel-
low).
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cates that the plasma membrane portions of their distrib-
utions are identical (Fig. 3C). These results are consistent
with the evidence that FAP-1 physically binds p75NTR in
vivo.
3.4. Interaction of FAP-1 with p75NTR is involved in the
regulation of TRAF6-mediated NF-UB activation
A recent report suggested that TRAF6 associates with
p75NTR, leading the localization of the p65 subunit of NF-
UB in Schwann cells [12]. To assess whether the interaction of
FAP-1 and p75NTR regulates the NF-UB activation mediated
by TRAF6, we measured the NF-UB of 293T cells transfected
with p75NTR, p75NTR (V396M), p75NTR (vSPV), or FAP-1 by
using a dual-luciferase assay system. Transfection of 293T
cells with FAP-1 or p75NTR alone did not a¡ect NF-UB acti-
vation in the absence of TRAF6 (data not shown). However,
co-expression with TRAF6 showed regulation of its NF-UB
activation. 293T cells were cotransfected with TRAF6, which
used at least 0.1 Wg per transfection, and FAP-1 enhanced
NF-UB activation in proportion to dose (Fig. 4A). In contrast,
p75NTR suppressed NF-UB activity mediated by TRAF6 in
proportion to the concentration of p75NTR (Fig. 4B). The
repression of NF-UB activation by p75NTR was signi¢cantly
decreased by FAP-1 expression (Fig. 4B). The suppression of
NF-UB activation was also decreased by FAP-1 when p75NTR
(V396M) or p75NTR (vSPV) was transfected instead of wild-
type p75NTR (Fig. 4C). Interactions of FAP-1 with p75NTR
(V396M) or p75NTR (vSPV) were not detected in 293T cell
transfectants (Fig. 4D). These results imply that the associa-
tion of FAP-1 and p75NTR may be related to down-regulation
of NF-UB activation, or that FAP-1, which does not bind to
p75NTR, may up-regulate NF-UB activation.
Fig. 4. E¡ects of interaction of FAP-1 with p75NTR on NF-UB activation in 293T cells. A: FAP-1 up-regulates TRAF6-mediated NF-UB activa-
tion. B: p75NTR down-regulates TRAF6-mediated NF-UB activation. C: Transfection of p75NTR (V396M) or pcDNA3-p75NTR (vSPV) up-regu-
lates TRAF6-mediated NF-UB activation. 293T cells were cotransfected with 1.4 Wg of pELAM-luc reporter plasmid, 0.1 Wg of pRL-TK and in-
dicated expression plasmids (pRc/CMV-FAP-1, pcDNA3-p75NTR, pcDNA3-p75NTR [V396M], pcDNA3-p75NTR [vSPV], pCMV-myc-TRAF6),
and control plasmid pcDNA3 to give 5 Wg of total DNA. After 24 h, NF-UB activity was determined by an E-selectin promoter-luciferase as-
say. Luciferase activity was measured with a dual-luciferase assay system (Promega) and normalized to the level of pRK-TK expression. The re-
sults presented are averages of three individual experiments. D: Interaction of FAP-1 with a wild-type p75NTR, but not with p75NTR (V396M)
or p75NTR (vSPV) mutants. Cell lysates prepared from 293T cells transiently cotransfected with control vectors pcDNA3 and pFLAG-CMV-2
(lane 1), pFLAG-CMV-2-hFAP-1 (lane 2), pcDNA3-p75NTR (lane 3), pcDNA3-p75NTR(V396M) (lane 4), pcDNA3-p75NTR(vSPV) (lane 5) and
their combinations were immunoprecipitated with anti-FLAG M2 monoclonal-antibody-coupled protein G Sepharose 4B. After incubation, the
beads were washed, and retained p75NTR protein was analyzed by Western blotting with anti-p75NTR polyclonal antibody.
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3.5. p75NTR C-terminal mutation (VCM) enhances its
pro-apoptotic activity
To determine the biological signi¢cance of the tSPV se-
quence of p75NTR, we examined the functional e¡ects of a
substitution mutation in the tSPV motif of p75NTR by using
a cell line expressing FAP-1. We ¢rst con¢rmed that FAP-1 is
endogenously expressed in 293T cells by RT-PCR and immu-
noblot analysis with a newly generated FAP-1 antibody (data
not shown). Immunoblot analysis did not detect expression of
endogenous p75NTR protein in 293T cells (data not shown).
Using this cell line, we transfected a mammalian expression
plasmid encoding the entire intracellular domain of wild-type
rat p75NTR (pcDNA3-p75NTR-ICD) or a mutant p75NTR-ICD
in which the C-terminal valine residue was replaced with a
methionine (pcDNA3-p75NTR-ICD [V396M]). It was shown
previously that overexpression of p75NTR in some types of
cells increases their sensitivity to various apoptotic stimuli
[4]. Interestingly, transfection of pcDNA3-p75NTR-ICD
(V396M) enhanced pro-apoptotic activity induced by tamox-
ifen, an anti-estrogen, anti-proliferative reagent, whereas the
wild-type p75NTR did not (Fig. 5A). The percentage of dead
cells in the pcDNA3-p75NTR-ICD (V396M) transfectants was
73 þ 16%, in contrast to only 12^14% in the pcDNA3 (con-
trol) and pcDNA3-p75NTR-ICD transfectants. Furthermore, a
wild-type p75NTR with an extracellular domain also showed
weak pro-apoptotic activity in the p75NTR (V396M) transfec-
tants (Fig. 5B). These results reveal that the V396M mutation
in the C-terminus of p75NTR increases the pro-apoptotic func-
tion of p75NTR, and imply that potential negative regulators,
such as FAP-1 sensitization, may be involved in suppressing
p75NTR-mediated signals that lead to apoptosis.
4. Discussion
We have shown clearly that FAP-1 physically interacts with
the cytoplasmic region of p75NTR both in vitro and in vivo,
and that this association is mediated through the interaction
between the third PDZ domain of FAP-1 and the tSPV motif
of p75NTR. This binding characteristic of FAP-1 is consistent
with previous ¢ndings that the third PDZ domain of FAP-1
speci¢cally recognizes the C-terminal (S/T)-X-V motif, indi-
cated by using random peptide libraries [21]. Because the
PDZ domains have been thought to contribute to the forma-
tion of a protein complex to trigger a signal transduction
[19,20], the interaction of the third PDZ domain of FAP-1
with the tSPV of p75NTR may also play an important role
in p75NTR-mediated signal transduction. Thus, FAP-1 is the
¢rst identi¢ed protein tyrosine phosphatase to interact with
p75NTR.
Interestingly, FAP-1 possesses a putative membrane bind-
ing domain similar to that found in the cytoskeleton-associ-
ated proteins ezrin [25], protein 4.1, and the neuro¢bromatosis
type II gene product [26], as well as in the PTPases PTPH1
[27] and PTP-MEG [28]. By £uorescence analysis of GFP/
FAP-1-expressing cells, we showed that FAP-1 is localized
in the plasma membrane, as speculated from the existence
of a putative membrane binding domain (Fig. 3). Co-local-
ization of FAP-1 and p75NTR at the cell membrane raises the
possibility of their interaction in mammalian cells. The FAP-1
mRNA is widely expressed in various tissues in vivo and is
present at particularly high levels in adult tissues such as
kidney, testis, and ovary, and at moderate levels in brain,
lung, prostate, and heart ([13,14]; and our data not shown).
Interestingly, the expression of FAP-1 in fetal tissues was
markedly higher in brain, kidney, and lung than in adult
tissues [13]. p75NTR is also highly expressed in the fetal brain.
It is possible that FAP-1 is involved in the regulation of
neuronal cell death by p75NTR-mediated signal transduction
pathways. In this regard, studies of p75NTR knock-out mice
have shown that the numbers of surviving neurons increased
in brain tissues known to express this receptor [29], implying a
pro-apoptotic role for p75NTR in the developing brain in vivo.
p75NTR is also expressed in non-neuronal tissues in adults
and fetuses ([30,31] ; and our data not shown). Therefore,
FAP-1 may potentially bind to p75NTR and transduce the
signals mediated by p75NTR in those tissues expressing both
of them.
The regulation of NF-UB activation through p75NTR is re-
lated to apoptosis in some cell lines [32,33]. NF-UB activity is
induced by NGF in primary Schwann cells expressing p75NTR
Fig. 5. E¡ect of mutation in the FAP-1 binding site (C-terminal SPV) of the intracellular domain of p75NTR to tamoxifen-induced apoptosis.
A: 293T cells were transfected with a control plasmid (pcDNA3), pcDNA3-p75NTRICD, or pcDNA3-p75NTRICD (V396M). After the cells were
washed with serum-free medium and placed on DMEM with 3% FBS, the cells were placed on 35 WM tamoxifen for 4^12 h. Viability was as-
sessed by propidium iodide £uorescence and trypan blue exclusion. B: 293T cells were transfected with a control plasmid (pcDNA3), pcDNA3-
p75NTR, or pcDNA3-p75NTR (V396M). Methods as in A. The results are derived from 3^6 individual experiments.
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but no TrkA receptors [2] and p75NTR associates with TRAF6
in an NGF-dependent manner [12]. The result that FAP-1 is
related to NF-UB activation by TRAF6 (Fig. 4) supports the
idea that FAP-1 might a¡ect the signaling of p75NTR to acti-
vate NF-UB. We did not test whether NF-UB activation stimu-
lated by NGF was a¡ected by FAP-1, but NF-UB activity
might be repressed when FAP-1 binds p75NTR and be accel-
erated by dissociation of FAP-1 from p75NTR without extra-
cellular signaling. Further studies are required to examine
whether FAP-1 and p75NTR dissociate in response to the bind-
ing of NGF to p75NTR and how the phosphatase activity of
FAP-1 relates to NF-UB activation.
We showed that the VCM substitution in the tSPV motif
at the C-terminus of p75NTR did not signi¢cantly enhance
tamoxifen-induced apoptosis caused by ectopic expression of
p75NTR in 293T cells that endogenously express FAP-1 (Fig.
5B). This implies that the dissociation of FAP-1 from the C-
terminus of p75NTR may be caused by signaling from an ex-
tracellular region of p75NTR necessary for tamoxifen-induced
apoptosis. The results also imply that FAP-1 may be a mod-
ular protein that regulates apoptotic signaling by p75NTR
through its dissociation from the tSPV motif of p75NTR. Be-
cause FAP-1 is a PTPase, this implicates tyrosine phosphoryl-
ation in some aspect of the pro-apoptotic signaling mechanism
by which p75NTR promotes cell death. It has previously
been shown that the ectopic expression of FAP-1 partially
inhibits Fas-mediated apoptosis and, moreover, that the ex-
pression level of the FAP-1 protein is correlated with resist-
ance to Fas-induced apoptosis in a variety of human tumor
cell lines [17]. FAP-1 therefore appears to be a negative reg-
ulator of Fas-mediated apoptosis. Among the members of the
TNFR superfamily, only p75NTR and Fas possess a t(S/T)-X-
V motif. Therefore, it can be speculated that p75NTR and Fas
share some mechanisms for regulating apoptosis.
It has been found that the Src homology 2 (SH2)-domain-
containing PTPases SHP-1 and SHP-2 are tyrosine-phos-
phorylated and -activated following NGF treatment in PC12
cells. SHP-1 associates with TrkA in vitro, and SHP-2 asso-
ciates with TrkA following TrkA receptor activation [34,35].
Thus, PTPases appear to play an important role in regulation
of TrkA-mediated signal transduction. Based on the binding
reported here, it is also possible that FAP-1 may participate
the level of tyrosine phosphorylation elicited by activation
of TrkA in the p75NTR-TrkA receptor complex. Further stud-
ies are required to establish whether any other molecules re-
lated to the signal transduction are dephosphorylated by
FAP-1.
In this report, we showed that the third PDZ domain of
FAP-1 interacts with the tSPV motif of p75NTR. This is the
¢rst demonstration that a PDZ-domain-containing protein in-
teracts with the C-terminus of p75NTR. Moreover, we provide
indirect evidence that FAP-1 might participate in regulation
of NF-UB activation and p75NTR-mediated pro-apoptotic sig-
naling pathways. FAP-1 is the largest of the known intracel-
lular protein tyrosine phosphatases, possessing 6 PDZ do-
mains. Through its multiple PDZ domains, FAP-1 may aid
in the assembly of multimeric complexes of proteins, including
p75NTR, NMDA receptors, iNOS, and Shaker-type K chan-
nels. Likewise, the binding of an S/T-X-L/V/I motif at the C-
terminus of p75NTR raises the possibility that other PDZ-do-
main-containing proteins besides FAP-1 may compete for
binding to this region of the p75NTR protein. Though much
remains to be determined concerning the role of FAP-1-
p75NTR interactions, the ¢ndings reported here reveal a pre-
viously unrecognized aspect of a neurotrophin receptor signal-
ing mechanism.
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